Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging
Article first published online: 17 MAY 2011
Copyright © 2011 Wiley-Liss, Inc.
Journal of Magnetic Resonance Imaging
Volume 33, Issue 6, pages 1284–1290, June 2011
How to Cite
Park, I., Bok, R., Ozawa, T., Phillips, J. J., James, C. D., Vigneron, D. B., Ronen, S. M. and Nelson, S. J. (2011), Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging. J. Magn. Reson. Imaging, 33: 1284–1290. doi: 10.1002/jmri.22563
- Issue published online: 17 MAY 2011
- Article first published online: 17 MAY 2011
- Manuscript Accepted: 14 FEB 2011
- Manuscript Received: 22 NOV 2010
- Academic-industry partnership grant from the UC Discovery program in conjunction with GE Healthcare. Grant Number: K08 NS063456-03 (to J.J.P.)
- dynamic nuclear polarization;
- hyperpolarized 13C MRSI;
- brain tumor;
- response to temozolomide
To demonstrate the feasibility of using DNP hyperpolarized [1-13C]-pyruvate to measure early response to temozolomide (TMZ) therapy using an orthotopic human glioblastoma xenograft model.
Materials and Methods:
Twenty athymic rats with intracranial implantation of human glioblastoma cells were divided into two groups: one group received an oral administration of 100 mg/kg TMZ (n = 10) and the control group received vehicle only (n = 10). 13C 3D magnetic resonance spectroscopic imaging (MRSI) data were acquired following injection of 2.5 mL (100 mM) hyperpolarized [1-13C]-pyruvate using a 3T scanner prior to treatment (day D0), at D1 (days from treatment) or D2.
Tumor metabolism as assessed by the ratio of lactate to pyruvate (Lac/Pyr) was significantly altered at D1 for the TMZ-treated group but tumor volume did not show a reduction until D5 to D7. The percent change in Lac/Pyr from baseline was statistically different between the two groups at D1 and D2 (P < 0.008), while percent tumor volume was not (P > 0.2).
The results from this study suggest that metabolic imaging with hyperpolarized [1-13C]-pyruvate may provide a unique tool that clinical neuro-oncologists can use in the future to monitor tumor response to therapy for patients with brain tumors. J. Magn. Reson. Imaging 2011;33:1284–1290. © 2011 Wiley-Liss, Inc.